DR-205 Identification of somatic variants of unknown significance affecting clinically actionable kinases
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- oncoanalyser
- OncoAnalyser Dx
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-205 Identification of somatic variants of unknown significance affecting clinically actionable kinases
Many genomic alterations affecting known driver genes are still classified as variants of unknown significance (VUS). Especially VUS other than …
DR-202 Evolution of resistance to endocrine therapies in breast cancer
Endocrine therapies remain a core component of systemic therapy for patients with estrogen receptor positive breast cancer, but all patients …
DR-194 Microbiome in metastatic cancer
In this study we will investigate the microbiome in metastatic cancer. We will use whole genome sequencing data from solid …
DR-192 A comprehensive analysis of germline / somatic interactions
Over the last decade we have made significant progress in understanding which mutations are acquired by healthy cells before becoming …
DR-190 Development and standardization of benchmarking strategies for identification of genomic variants in cancer
As part of the EUCANCan project, a federated network for harmonized genomic and phenotypic data sharing, we aim to foster …
DR-189 Validating the Utility of Meta-Analysis for Learning Translatable Predictive Models from in vitro Pharmacogenomics
Several large initiatives have profiled cancer cell lines – lab grown models of disease – for their response to panels …
DR-186 Comprehensive evaluation of microbial organisms in human metastatic cancers and their influence on local immunity
We have shown that many human cancer types can be diagnosed using microbial DNA and RNA from patients’ primary tumors …
DR-181 Germline-Somatic Correlates for Cancer Drug Sensitivity and Survival
The goal of this project is to determine how germline mutations influence somatic mutation signatures, drug response, and survival. We …
DR-179 The impact of non-coding/regulatory mutations on cancer susceptibility and response to targeted therapies.
In terms of the research on genetic predisposition to cancers, recent advances in DNA sequencing technologies are facilitating the discovery …
DR-175 “Comparing metastatic and primary breast tumours through the lens of integrated subtypes – RNA-seq. DR-175 is an extension of DR-129”
This request is an extenstion of DR-129 to include RNA data. The Personalised Breast Cancer Program (PBCP) is an initiative …
DR-168 Defining mutational signatures of childhood cancer treatments
Numerous environmental triggers have been found to leave a mutational footprint on the DNA of human cancers. In our lab, …
DR-167 Health related quality of life and utilities in patients with locally advanced and metastatic cancer, treated with or without personalised treatment based on Whole Genome Sequencing.
The effect on health related quality of life (HRQoL) of patients treated with or without personalized treatment based on WGS …
De complete DNA-test is een belangrijke stap op weg naar behandeling van vormen van kanker die nu nog niet behandeld kunnen worden met doelgerichte medicijnen.